All In Biotech

Drug Trial Radar · NCT07868939

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 68-Week Efficacy and Safety Study of VK2735 Administered Orally for Weight Management in Participants With Type 2 Diabetes Mellitus Who Are Obese, or Overweight

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Viking Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Conditions

  • Weight Loss

Interventions

  • VK2735 OralDrug

    VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

  • Placebo ComparatorDrug

    Placebo comparator administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once dailyTime frame: 68 weeks

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Viking Clinical Site #2020

    Tucson, Arizona · Recruiting

  • Viking Clinical Site #2015

    Lake Forest, California · Recruiting

  • Viking Clinical Site #2059

    Ocoee, Florida · Recruiting

  • Viking Clinical Site #2013

    Atlanta, Georgia · Recruiting

  • Viking Clinical Site #2001

    Evansville, Indiana · Recruiting

  • Viking Clinical Site #2046

    Indianapolis, Indiana · Recruiting

  • Viking Clinical Site #2009

    Valparaiso, Indiana · Recruiting

  • Viking Clinical Site #2004

    Richfield, Minnesota · Recruiting

  • Viking Clinical Site #2029

    Jackson, Mississippi · Recruiting

  • Viking Clinical Site #2028

    Springfield, Missouri · Recruiting

  • Viking Clinical Site #2052

    Albuquerque, New Mexico · Recruiting

  • Viking Clinical Site #2039

    Binghamton, New York · Recruiting

  • Viking Clinical Site #2023

    Medford, Oregon · Recruiting

  • Viking Clinical Site #2002

    East Greenwich, Rhode Island · Recruiting

  • Viking Clinical Site #2044

    Charleston, South Carolina · Recruiting

  • Viking Clinical Site #2030

    Hendersonville, Tennessee · Recruiting

  • Viking Clinical Site #2031

    Abilene, Texas · Recruiting

  • Viking Clinical Site #2011

    Seattle, Washington · Recruiting

  • Viking Clinical Site #2042

    Spokane, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.